SG11201706824TA - Crystalline forms of a pyrrolopyridine compound - Google Patents

Crystalline forms of a pyrrolopyridine compound

Info

Publication number
SG11201706824TA
SG11201706824TA SG11201706824TA SG11201706824TA SG11201706824TA SG 11201706824T A SG11201706824T A SG 11201706824TA SG 11201706824T A SG11201706824T A SG 11201706824TA SG 11201706824T A SG11201706824T A SG 11201706824TA SG 11201706824T A SG11201706824T A SG 11201706824TA
Authority
SG
Singapore
Prior art keywords
crystalline forms
pyrrolopyridine compound
pyrrolopyridine
compound
crystalline
Prior art date
Application number
SG11201706824TA
Other languages
English (en)
Inventor
Jeffrey Stults
Christopher M Lindemann
Keith L Spencer
Weidong Liu
Joseph Lubach
Original Assignee
Genentech Inc
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55521844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201706824T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Array Biopharma Inc filed Critical Genentech Inc
Publication of SG11201706824TA publication Critical patent/SG11201706824TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201706824TA 2015-02-26 2016-02-26 Crystalline forms of a pyrrolopyridine compound SG11201706824TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562121396P 2015-02-26 2015-02-26
PCT/US2016/019904 WO2016138458A1 (fr) 2015-02-26 2016-02-26 Formes cristallines d'un composé pyrrolopyridine

Publications (1)

Publication Number Publication Date
SG11201706824TA true SG11201706824TA (en) 2017-09-28

Family

ID=55521844

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201706824TA SG11201706824TA (en) 2015-02-26 2016-02-26 Crystalline forms of a pyrrolopyridine compound

Country Status (21)

Country Link
US (2) US20160251350A1 (fr)
EP (1) EP3262042A1 (fr)
JP (1) JP2018506562A (fr)
KR (1) KR20170118762A (fr)
CN (1) CN107406447A (fr)
AR (1) AR103801A1 (fr)
AU (1) AU2016225070A1 (fr)
BR (1) BR112017018230A2 (fr)
CA (1) CA2976665A1 (fr)
CL (1) CL2017002180A1 (fr)
CO (1) CO2017009662A2 (fr)
CR (1) CR20170439A (fr)
HK (1) HK1246786A1 (fr)
IL (1) IL254115A0 (fr)
MA (1) MA41599A (fr)
MX (1) MX2017010888A (fr)
PE (1) PE20171327A1 (fr)
PH (1) PH12017501532A1 (fr)
RU (1) RU2017133093A (fr)
SG (1) SG11201706824TA (fr)
WO (1) WO2016138458A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3128152A1 (fr) * 2019-01-29 2020-08-06 Huya Bioscience International, Llc Sels de sulcardine
EP3923948A4 (fr) * 2019-02-12 2022-11-16 Impact Biomedicines, Inc. Formes cristallines d'un inhibiteur de jak2

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
US8481557B2 (en) * 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
RU2017127088A (ru) * 2010-11-16 2019-02-04 Эррэй Биофарма Инк. Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1
MX369174B (es) * 2013-08-22 2019-10-30 Genentech Inc Proceso para la preparación de un compuesto.
WO2015027090A1 (fr) * 2013-08-22 2015-02-26 Genentech, Inc. Intermédiaires et procédés pour la préparation de composés

Also Published As

Publication number Publication date
CN107406447A (zh) 2017-11-28
KR20170118762A (ko) 2017-10-25
HK1246786A1 (zh) 2018-09-14
US20160251350A1 (en) 2016-09-01
US20180282324A1 (en) 2018-10-04
CL2017002180A1 (es) 2018-03-16
CR20170439A (es) 2018-01-08
AU2016225070A1 (en) 2017-09-07
WO2016138458A1 (fr) 2016-09-01
CO2017009662A2 (es) 2018-02-28
JP2018506562A (ja) 2018-03-08
PE20171327A1 (es) 2017-09-12
MX2017010888A (es) 2017-12-15
AR103801A1 (es) 2017-06-07
PH12017501532A1 (en) 2018-02-05
CA2976665A1 (fr) 2016-09-01
IL254115A0 (en) 2017-10-31
BR112017018230A2 (pt) 2018-04-17
EP3262042A1 (fr) 2018-01-03
RU2017133093A (ru) 2019-03-26
MA41599A (fr) 2018-01-02
RU2017133093A3 (fr) 2019-08-23

Similar Documents

Publication Publication Date Title
IL263429A (en) Crystalline forms of a triazolopyrimidine compound
IL281292B1 (en) Processes for preparing a diarylthiohydantoin compound
HK1247125A1 (zh) 結晶化合物
SI3380554T1 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
IL254530A0 (en) Preparation method of crystalline form a of pci-32765
HK1244274A1 (zh) C21h22ci2n4o2的晶型
GB201522771D0 (en) Crystalline form of a phosphate derivative
HUE066360T2 (hu) Eravaciklin kristályformái
IL253479A0 (en) Crystalline forms of efinconazole
HK1252842A1 (zh) 噻吩並嘧啶化合物的結晶形式
HK1246786A1 (zh) 吡咯並吡啶化合物的結晶形式
ZA201606653B (en) Solid forms of a pharmaceutically active compound
HK1252841A1 (zh) 噻吩並嘧啶化合物的鹽酸鹽的結晶形式
ZA201607107B (en) Salts and polymorphs of a substituted imidazopyridinyl-aminopyridine compound
GB201704789D0 (en) Crystalline compounds
GB201604759D0 (en) Crystalline compounds